Navigating the Pharmaceutical Patent Landscape: Impact of Patent Cliffs on Innovation and Accessibility

This research paper analyses the impact of patent cliffs on both pharmaceutical firms and patients, focusing on the dynamics that emerge when brand-name drugs lose patent protection. Through an extensive literature review, the paper examines the various strategies employed by firms to mitigate the financial consequences of patent cliffs. Despite these efforts to preserve revenue, these strategies often have unintended consequences for patients, including limited access to affordable medications and delayed availability of generics. Moreover, the paper explores how certain firms, in their pursuit of profit, have sometimes overlooked ethical considerations, legal regulations, and patient well-being. The analysis further highlights the ethical dilemma faced by the pharmaceutical industry, which involves balancing the pursuit of profit with the responsibility to ensure access to essential treatments. This paper concludes by discussing the need for a more ethical approach to patent management that prioritises patient health without compromising the financial sustainability of the industry.